Table 1.
Patients, n (%) |
||
---|---|---|
BEV + RT/TMZ (n = 458) |
Plb + RT/TMZ (n = 463) |
|
End of treatment break | ||
Potential pseudoprogression | 12 (2.6) | 84 (18.1) |
End of second maintenance cycle | ||
Confirmed pseudoprogression | 10 (2.2) | 43 (9.3) |
Confirmed progression | 1 (0.2) | 35 (7.6) |
Missing | 1 (0.2) | 6 (1.3) |
Abbreviations: BEV, bevacizumab; Plb, placebo.